Sunday, October 27, 2013

OxBridge Research initiates coverage of Teryl Resources,TRC.V, with a price target of 14 cents

Teryl Resources, TRC.V / TRYLF

OxBridge Research, a leading provider of investment research and investor relations services, today announced that it has initiated coverage of Teryl Resources with a price target of 14 cents.

Teryl Resources is a Junior Gold Mining company with assets in Fairbanks Mining District in Alaska and British Columbia. The Fairbanks Mining District is one of Alaska’s largest gold producing areas – gold production of over 40 million ounces.

The 31 page Report covers, Teryl's properties, its various Joint Venture partners including Kinross Gold Corporation (KGC) and Linux Gold Corp. (LNXGF) and future Gold market outlook.

The full Report is available for download for FREE at http://www.oxbridgeresearch.com/ and http://www.terylresources.com/ in addition to this Initiation Report, OxBridge Research will also provide ongoing coverage and event-based research updates on the Company.

Company Description

Teryl Resources Corp., TRC.V, is an early stage Canadian junior precious metals acquisition, exploration, and development company which holds interests in gold and silver properties in Alaska and British Columbia, Canada. Click here for complete Executive Summary

The Company is an accomplished explorer with a proven track record of exploration, development, and marketing its properties to mining majors. The Company has three properties in Alaska and one property in British Columbia. Teryl’s properties in Alaska are in the Fairbanks Mining District and include the West Ridge Property, Fish Creek Property, and Stepovich Property. Learn more about Teryl's strategy, see the Investment Highlights

The Fairbanks Mining District is one of the largest gold producing areas in Alaska. In 2011, Teryl sold its 20% stake in Gil Properties to Kinross Gold for US$15 million. see Teryl's Valuation

The Company’s single property in British Columbia is its Silverknife Property. Teryl also has oil and gas properties in Texas and Kentucky. To date, Teryl has spent over $2.2 million on exploration of its properties. Find out why the Analyst thinks the stock is undervalued, read Investment Thesis now


Sources: Teryl Resources Corp., Kinross Gold Corp., Linux Gold Corp., SilverCorp.

Forward-looking statements:-The Company's actual results, performance or achievements could differ materially from those expressed in, or implied by, these forward-looking statements, including those described in the Company's Financial Statements, Management Discussion and Analysis and Material Change Reports filed with the Canadian Securities Administrators and available at www.sedar.com, and the Company's 20-F annual report filed with the United States Securities and Exchange Commission at www.sec.gov.
This profile/research report/email letter/blog/posting in forums/social-media/t/f does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities of the Company have not been registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Disclosure/Disclaimer:-OxBridge Research publishes sponsored research reports, advertorials and corporate profiles on its portal and several other websites/blogs, including this website/blog, owned and operated by OxBridge and/or its affiliates. OxBridge Research is not a Broker Dealer or a Registered Financial Adviser in any jurisdiction, whatsoever. All the information published on its website(s) and/or distributed to its members via various electronic means is for general awareness and entertainment purpose only. OxBridge urges investors to do their own due diligence and consult with their financial adviser prior to making any investment decision. We are expecting a payment of seven thousand dollars in compensation from the company/a third party/shareholder. We receive compensation from companies for providing various IR services, including consultation, publication, advertisement and social media awareness, therefore our views/opinion are inherently biased. Please read the full disclosure/disclaimer, if you need assistance contact Editor@OxBridgeResearch.com OxbridgeResearch.com, All Rights Reserved. Trademarks/logos are of their respective owners. It's YOUR money -Invest WISELY TM

Monday, October 21, 2013

SIFY our pick from 10/10 up 20% today! Hot stocks, RSOL, NCTY, REDF, Profit from our insight, Get Daily Stock Deals, Picks & Alerts

Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!®
we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.

Tuesday, October 8, 2013

Daily Stock Deals ‏@TOP10STOCKS 3m $STEV kicking ass! UP 20% learn more http://oxbridgeresearch.com/docs/Stevia,STEV,Research%20Report.pdf … #stevia #stev #hotstock #hotpennystock #traders #marketnews

Daily Stock Deals ‏@TOP10STOCKS 48s New Benjamins, high tech $100 bills http://www.newmoney.gov/uscurrency/redesigned100.htm … … … #benjamins $100 #newmoney #Money http://www.dailystockdeals.com

Hot Stock Picks for 10/08/2013:RCON, SOL, AGEN, Profit from our insight! Get Daily Stock Deals and Alerts

Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!®
Get the Fresh, Piping Hot Picks Everyday! Sign-up, its FREE!

Monday, October 7, 2013

Daily Stock Deals ‏@TOP10STOCKS 1m Our Featured company: $TTNP up a whopping 23% update by http://www.dailystockdeals.com/featured-deal/blog … @TOP10picks #hotpicks #hotstocks #pennystocks @TOP10STOCKS

Titan Pharmaceuticals, TTNP, Profile, Summary


Titan Pharmaceuticals | TTNP | Profile | Summary

Titan Pharmaceuticals, Inc. is a biopharmaceutical Company developing proprietary therapeutics primarily for the treatment of serious medical disorders.

Titan’s principal asset is Probuphine®, the first slow-release implant formulation of buprenorphine hydrochloride (“buprenorphine”), designed to maintain a stable, round-the-clock blood level of the medicine in patients for up to six months following a single treatment. The outpatient treatment of opioid dependence with daily dosed sublingual buprenorphine formulations represents a $1.3 billion market in the U.S., and a seven day transdermal patch formulation of buprenorphine for the treatment of chronic pain was launched in the U.S. in 2011. This novel implant formulation is inserted subdermally in a patient’s upper arm providing continuous medication, and has the potential to enhance patient compliance to treatment, and limit diversion for illicit use and accidental exposure to the sublingual formulations.

The New Drug Application (NDA) was submitted to the FDA in October, 2012 seeking approval for treatment of opioid dependence. In December 2012, Titan entered into a license agreement with Braeburn Pharmaceuticals Sprl (“Braeburn”) that grants Braeburn exclusive commercialization rights to Probuphine® in the United States and Canada. Titan received a non-refundable up-front license fee of $15.75 million and will receive a $50 million milestone payment upon the approval of the NDA by the FDA. Additionally, Titan will be eligible to receive up to $130 million upon achievement of specified sales milestones and up to $35 million in regulatory milestones in the event of future NDA submissions and approvals for additional indications, including chronic pain. Titan will receive tiered royalties on net sales of Probuphine ranging from the mid-teens to the low twenties.

Probuphine is the first product to utilize ProNeura™, a novel, proprietary, long-term drug delivery technology. The ProNeura technology has the potential to be used in developing products for the treatment of other chronic conditions, such as Parkinson’s disease, where maintaining stable, round-the-clock blood levels of a drug can benefit the patient and improve medical outcomes.

Continuous Drug Delivery Technology
The continuous drug delivery system consists of a small, solid rod made from a mixture of ethylene-vinyl acetate (“EVA”) and a drug substance. The resulting product is a solid matrix that is placed subcutaneously, normally in the inner part of the upper arm in a simple office procedure, and is removed in a similar manner at the end of the treatment period. The drug substance is released slowly, at continuous levels, through the process of dissolution. This results in a stable blood level similar to intravenous administration. Such long-term, linear release characteristics are generally desirable as this avoids peak and trough level dosing that poses problems for many Central Nervous System (“CNS”) and other disease settings.

This continuous drug delivery technology was developed to address the need for a simple, practical method to potentially provide continuous drug administration on an outpatient basis over extended periods of up to 6-12 months. In addition to Probuphine, which is the first product to complete clinical testing that has utilized this proprietary continuous drug delivery technology, Titan has conducted initial non-clinical studies with long-term delivery of dopamine agonists demonstrating the potential of this product in the treatment of Parkinson’s disease in non-clinical models of the disease.

Strategic Alliances
In December 2012, Titan entered into a license agreement with Braeburn Pharmaceuticals Sprl (“Braeburn”) that grants Braeburn exclusive commercialization rights to Probuphine® in the United States and Canada. Titan received a non-refundable up-front license fee of $15.75 million and will receive a $50 million milestone payment upon the approval of the NDA by the FDA. Additionally, Titan will be eligible to receive up to $130 million upon achievement of specified sales milestones and up to $35 million in regulatory milestones in the event of future NDA submissions and approvals for additional indications, including chronic pain. Titan will receive tiered royalties on net sales of Probuphine ranging from the mid-teens to the low twenties.

Novartis Pharma, AG, has licensed the rights to commercialize Fanapt in the U.S. and Canada, and commenced marketing the product in the U.S. in Q1, 2010. Titan is entitled to receive a royalty of 8-10% on the global net sales of this product. Titan does not incur any expenses related to this product.

Source: Titan Pharmaceuticals, OxBridge Research, Daily Stock Deals, OTC King. PSM

Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!®
we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks. OTCking.com is an OxBridge affiliate/partner website.
Disclosure/Disclaimer:- OxBridge Research publishes sponsored research reports, advertorials and corporate profiles on its portal and several other websites/blogs, including this website/blog, owned and operated by OxBridge and/or its affiliates. OxBridge Research is not a Broker Dealer or a Registered Financial Adviser in any jurisdiction, whatsoever. All the information published on its website(s) and/or distributed to its members via various electronic means is for general awareness and entertainment purpose only. OxBridge urges investors to do their own due diligence and consult with their financial adviser prior to making any investment decision. We are expecting a payment from the company/a third party/shareholder. We receive compensation from companies for providing various IR services, including publication, advertisement,and social media awareness, therefore our views/opinion are inherently biased. Please read the full disclosure/disclaimer, if you need assistance contact Editor@OxBridgeResearch.com
OxbridgeResearch.com, All Rights Reserved. Trademarks/logos are of their respective owners.
It's YOUR money - Invest WISELY TM

Daily Stock Deals ‏@TOP10STOCKS 3m Easy Money! Don't miss: 2 Bank Stocks $ALBKY $NGB #urgent #update byhttp://www.dailystockdeals.com/ #easymoney #bank @TOP10picks #hot #news

  1. Easy Money! Don't miss: 2 Bank Stocks byhttp://www.dailystockdeals.com/

Friday, October 4, 2013

Hot Stock Picks for 10/04/2013: ZOOM,DSCO,IDRA, QUIK, Profit from our insight! Get Daily Stock Deals and Alerts

Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!®
we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.

Thursday, October 3, 2013

Hot Stock Picks for 10/03/2013: ASTI, GSS, MSTX, Profit from our insight! Get Daily Stock Deals and Alerts

Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!®
we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.